Ekso Bionics Holdings, INC

ChronoScale Corporation has successfully completed a holding company formation transaction, creating ChronoScale Holdings Corporation as the new parent entity without shareholder dilution.

ChronoScale Corporation (formerly Ekso Bionics Holdings, Inc.) has filed an amendment to its Form 8-K to include financial statements and pro forma information following its business combination with Applied Digital Cloud Corporation.

ChronoScale Corporation announced the expansion of its Board of Directors to eight members with the appointment of Andrew Cordell Schaap, who will also serve on the Audit and Related Party Transactions Committees.

ChronoScale Corporation has entered into a $100 million unsecured demand grid promissory note with Applied Digital Corporation for working capital.

ChronoScale Corporation announced its Board of Directors has committed to divesting its wholly owned subsidiary, Ekso Bionics, Inc., to concentrate solely on its cloud business.

ChronoScale Corporation has amended executive phantom stock unit awards to allow for equity-based settlement following a change in control.

Ekso Bionics reports Q1 2026 financial results, highlighting a net loss of $6.9 million and ongoing efforts to finalize a business combination with Applied Digital Cloud.

Ekso Bionics Holdings, Inc. reported a 2% revenue increase and a significant reduction in net loss for Q3 2025, while addressing going concern doubts and pursuing strategic transactions.

Ekso Bionics Holdings, Inc. reported a significant drop in second-quarter revenue and an increased operating loss, leading management to express substantial doubt about its ability to continue as a going concern without further financing.

Ekso Bionics' Q1 2025 revenue decreased by 10% year-over-year, driven by lower average selling prices in Enterprise Health and reduced EVO sales, while the company focuses on refining its CMS reimbursement process for Personal Health products.

Ekso Bionics' Q3 2024 results show a decrease in revenue compared to the same period last year, alongside reduced operating expenses and a net loss.

Ekso Bionics' second quarter 2024 results show a slight revenue decrease but improved gross margins and reduced operating expenses, alongside ongoing efforts to secure funding and navigate market challenges.

Ekso Bionics Holdings, Inc. has filed an amended annual report (Form 10-K/A) to include Part III information and updated certifications.

Ekso Bionics Holdings, Inc. reported a 29% decrease in revenue for 2025 and announced a definitive agreement to merge with Applied Digital Cloud Corporation, with the combined entity to be renamed ChronoScale Corporation.

Ekso Bionics' 2024 10-K filing reveals a year of strategic shifts, including CMS reimbursement approval for Ekso Indego Personal, alongside ongoing financial losses and efforts to refine operational efficiencies.

Ekso Bionics' 10-K filing outlines the details of its common stock, including dividend and voting rights, and describes anti-takeover provisions under Nevada law.

Rajasekar Jegannathan, Chief Technology Officer of Ekso Bionics Holdings, Inc., received 1,400,000 shares of common stock on July 22, 2026.

Ying Cenly Chen, Chief Executive Officer and a Director of Ekso Bionics Holdings, Inc., received 2,800,000 shares of common stock on July 13, 2026.

ChronoScale Corp director Andrew Schaap acquired 200,000 restricted shares of common stock on June 29, 2026, as part of a grant with a two-year vesting schedule.

Director William M. Clancy was granted 200,000 restricted shares of ChronoScale Corp common stock on May 14, 2026.

Director Wes Cummins was granted 200,000 restricted shares of ChronoScale Corp common stock, vesting over a two-year period.

Director Ella G. Benson was granted 200,000 restricted shares of ChronoScale Corp common stock on May 14, 2026.

Ekso Bionics is asking stockholders to approve a reverse stock split, an amendment to its equity incentive plan, and the issuance of shares upon exercise of a warrant at its upcoming annual meeting.

Ekso Bionics has released a supplement to its definitive proxy statement to correct the year reference for the term of directors elected at the upcoming annual meeting.

Ekso Bionics Holdings, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Ekso Bionics is holding its 2024 Annual Meeting of Stockholders on June 6, 2024, to vote on key proposals including the election of directors, extension of the equity incentive plan, and executive compensation.

Ekso Bionics is undertaking a firm commitment underwritten public offering of units and warrants to raise capital for general corporate purposes, including expansion and R&D.

Ekso Bionics is launching a public offering of common stock and pre-funded warrants to raise capital for general corporate purposes, including expansion and R&D.

Applied Digital Corporation has established a $100 million unsecured demand grid promissory note to support ChronoScale Corp's working capital needs.

Applied Digital Corporation has acquired a 97.5% controlling interest in ChronoScale Corporation following a business combination and private placement.

Armistice Capital, LLC and Steven Boyd have reported a 4.99% stake in Ekso Bionics Holdings, Inc. as of March 31, 2026.

Mink Brook Partners LP and affiliated entities have filed a Schedule 13G, reporting no beneficial ownership of ChronoScale Corp common stock as of May 14, 2026.

Mink Brook Partners LP, along with affiliated entities and William Mueller, has reported beneficial ownership of 190,596 shares, representing 5.4% of Ekso Bionics Holdings, Inc. common stock.

Daniel Asher and affiliated entities increased their beneficial ownership in Ekso Bionics Holdings, Inc. to 16.51% following a preferred share conversion.

Daniel Asher and DBA Trading, LLC have reported a significant passive stake in Ekso Bionics Holdings, Inc., acquiring additional shares in late December.

Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 9.99% of Ekso Bionics Holdings, Inc. common stock as of June 30, 2025.